AtriCure (NASDAQ:ATRC) Raised to "Hold" at StockNews.com
AtriCure (NASDAQ:ATRC) Raised to "Hold" at StockNews.com
AtriCure (NASDAQ:ATRC – Get Rating) was upgraded by StockNews.com from a "sell" rating to a "hold" rating in a research report issued on Wednesday.
在周三发布的一份研究报告中，斯托克新闻网将AtriCure(纳斯达克代码：ATRC-GET Rating)的评级从卖出上调至持有。
Several other research analysts also recently issued reports on ATRC. BTIG Research cut their price target on AtriCure from $94.00 to $75.00 and set a "buy" rating for the company in a research note on Friday, June 24th. Needham & Company LLC raised their target price on shares of AtriCure from $55.00 to $65.00 and gave the company a "buy" rating in a report on Wednesday, August 3rd. Stifel Nicolaus reduced their price target on shares of AtriCure from $70.00 to $50.00 in a report on Monday, July 18th. Finally, Piper Sandler dropped their price objective on shares of AtriCure from $90.00 to $55.00 and set an "overweight" rating for the company in a research note on Wednesday, August 3rd. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat, AtriCure currently has an average rating of "Moderate Buy" and an average target price of $75.86.
其他几位研究分析师最近也发布了关于ATRC的报告。BTIG Research将AtriCure的目标价从94.00美元下调至75.00美元，并在6月24日(星期五)的一份研究报告中为该公司设定了“买入”评级。Needham&Company LLC在8月3日周三的一份报告中将AtriCure的股票目标价从55.00美元上调至65.00美元，并给予该公司“买入”评级。Stifel Nicolaus在7月18日星期一的一份报告中将AtriCure的股票目标价从70.00美元下调至50.00美元。最后，派珀·桑德勒在8月3日星期三的一份研究报告中将AtriCure的股票目标价从90.00美元下调至55.00美元，并为该公司设定了“增持”评级。一名投资分析师对该股的评级为持有，五名分析师对该公司股票的评级为买入。根据MarketBeat的数据，AtriCure目前的平均评级为“中等买入”，平均目标价为75.86美元.
AtriCure Price Performance
AtriCure性价比
AtriCure stock traded up $1.25 during mid-day trading on Wednesday, reaching $44.07. The company had a trading volume of 294,105 shares, compared to its average volume of 264,289. The stock's 50-day simple moving average is $46.47 and its 200-day simple moving average is $50.65. AtriCure has a 1 year low of $32.83 and a 1 year high of $89.18. The company has a debt-to-equity ratio of 0.15, a current ratio of 3.66 and a quick ratio of 2.93. The company has a market capitalization of $2.05 billion, a P/E ratio of 37.99 and a beta of 1.21.
周三午盘交易中，AtriCure的股价上涨了1.25美元，达到44.07美元。该公司的成交量为294,105股，而其平均成交量为264,289股。该股的50日简单移动均线切入位为46.47美元，200日简单移动均线切入位为50.65美元。AtriCure的一年低点为32.83美元，一年高位为89.18美元。该公司的债务权益比为0.15，流动比率为3.66，速动比率为2.93。该公司市值20.5亿美元，市盈率为37.99倍，贝塔系数为1.21。
Institutional Trading of AtriCure
AtriCure的机构交易
Several hedge funds and other institutional investors have recently bought and sold shares of ATRC. Millennium Management LLC boosted its holdings in shares of AtriCure by 196.2% during the fourth quarter. Millennium Management LLC now owns 990,170 shares of the medical device company's stock worth $68,847,000 after purchasing an additional 655,861 shares during the last quarter. Alliancebernstein L.P. boosted its stake in AtriCure by 18.7% in the 4th quarter. Alliancebernstein L.P. now owns 3,455,856 shares of the medical device company's stock worth $240,286,000 after buying an additional 544,296 shares during the last quarter. Invesco Ltd. grew its holdings in AtriCure by 17.5% in the 1st quarter. Invesco Ltd. now owns 2,865,409 shares of the medical device company's stock valued at $188,171,000 after buying an additional 427,792 shares during the period. First Light Asset Management LLC increased its stake in shares of AtriCure by 35.8% during the 1st quarter. First Light Asset Management LLC now owns 1,364,812 shares of the medical device company's stock valued at $89,627,000 after acquiring an additional 359,823 shares during the last quarter. Finally, Granite Investment Partners LLC purchased a new position in shares of AtriCure during the 2nd quarter worth about $9,059,000. 95.21% of the stock is owned by hedge funds and other institutional investors.
几家对冲基金和其他机构投资者最近买卖了ATRC的股票。千禧管理有限责任公司在第四季度增持了196.2%的AtriCure股票。Millennium Management LLC现在持有这家医疗设备公司990,170股股票，价值68,847,000美元，上个季度又购买了655,861股。联合伯恩斯坦公司在第四季度将其在AtriCure的持股增加了18.7%。联合伯恩斯坦公司现在拥有这家医疗设备公司3,455,856股股票，价值240,286,000美元，上个季度又购买了544,296股。景顺在第一季度增持了AtriCure 17.5%的股份。景顺公司目前持有这家医疗设备公司2,865,409股股票，价值188,171,000美元，在此期间又购买了427,792股。First Light Asset Management LLC在第一季度增持了AtriCure股份35.8%。First Light Asset Management LLC现在拥有这家医疗器械公司1,364,812股股票，价值89,627,000美元，在上个季度额外收购了359,823股。最后，Granite Investment Partners LLC在第二季度购买了AtriCure的新头寸，价值约9,059,000美元。95.21%的股票由对冲基金和其他机构投资者持有。
AtriCure Company Profile
AtriCure公司简介
(Get Rating)
(获取评级)
AtriCure, Inc develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation.
AtriCure公司为美国、欧洲、亚洲和国际的医疗中心开发、制造和销售心脏组织和系统以及肋间神经的外科消融设备。该公司提供一次性射频产品Isolator Synergy Clip；多功能笔和线性消融设备，如Max Pen设备，使外科医生能够使用相同的设备评估心律失常、执行临时心脏起搏、传感和刺激并消融心脏组织；以及Coolail设备，使用户能够进行更长的线性消融。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on AtriCure (ATRC)
- REV Group Has A Deep Moat In The World Of EVs
- Is G-III Apparel Group, Ltd. A Value Trap?
- Bank Of America Sees Upside In These 2 European Alcohol Stocks
- 3 Low Beta Defensive Stocks for a Tough Market
- It Could Be a September to Remember for These 3 Stocks
- 免费获取StockNews.com关于AtriCure的研究报告(ATRC)
- REV集团在电动汽车世界拥有深厚的护城河
- G-III服装集团有限公司是价值陷阱吗？
- 美国银行看好这两只欧洲酒类股票
- 3低贝塔防御性股票为艰难的市场做准备
- 对于这三只股票来说，这可能是一个值得记住的9月
Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.
接收AtriCure日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对AtriCure和相关公司的最新新闻和分析师评级的每日简要摘要。